Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
Diabetes Mellitus, Non-Insulin-Dependent
0.100 GeneticVariation disease GWASCAT Genome-wide association studies in the Japanese population identify seven novel loci for type 2 diabetes. 26818947 2016
ANOPHTHALMIA AND PULMONARY HYPOPLASIA
0.020 Biomarker disease BEFREE In this study, through the analysis of C16orf74 interaction, we demonstrate a new strategy to inhibit the growth and invasion of PDAC. 31597713 2020
CUI: C0027651
Disease: Neoplasms
Neoplasms
0.020 Biomarker group BEFREE DN-C16orf74 also exhibited anti-tumor effects in orthotopic xenograft model. 29371937 2017
ANOPHTHALMIA AND PULMONARY HYPOPLASIA
0.020 Biomarker disease BEFREE DN-C16orf74 suppressed PDAC cell proliferation, and the level of suppression depended on the expression levels of C16orf74 <i>in vitro</i>. 29371937 2017
CUI: C0027651
Disease: Neoplasms
Neoplasms
0.020 AlteredExpression group BEFREE C16orf74 mRNA levels were examined by real-time reverse transcriptase polymerase chain reaction (RT-PCR) analysis of 193 tumor specimens from patients with primary NMIBC. 21203532 2010
CUI: C0235974
Disease: Pancreatic carcinoma
Pancreatic carcinoma
0.010 Biomarker disease BEFREE Thus, this study demonstrates that dimerized C16orf74, present in the cell membrane, is involved in pancreatic cancer invasion and proliferation. 31597713 2020
CUI: C0346647
Disease: Malignant neoplasm of pancreas
Malignant neoplasm of pancreas
0.010 Biomarker disease BEFREE Thus, this study demonstrates that dimerized C16orf74, present in the cell membrane, is involved in pancreatic cancer invasion and proliferation. 31597713 2020
CUI: C1269955
Disease: Tumor Cell Invasion
Tumor Cell Invasion
0.010 Biomarker phenotype BEFREE Thus, this study demonstrates that dimerized C16orf74, present in the cell membrane, is involved in pancreatic cancer invasion and proliferation. 31597713 2020
Carcinoma of urinary bladder, invasive
0.010 AlteredExpression disease BEFREE C16orf74 expression level represents a potentially useful marker for predicting progression in primary NMIBC patients. 21203532 2010